After #MeToo, Japan sexual abuse survivors seek reform in rape law through #WithYou

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Washington, Jun 13: America's first-ever Hindu lawmaker Tulsi Gabbard has said that in this chaotic time, one can find certainty, strength, and peace in Bhagavad Gita.

In her message during a virtual commencement address, the 39-year-old Congresswoman from Hawaii said that it is a chaotic time and no one can say with certainty what tomorrow looks like.

"... but we find certainty, strength, and peace in the practice of Bhakti Yoga and Karma Yoga taught to us by Krishna in the Bhagavad Gita," Tulsi Gabbard told the 'Class of 2020 for Hindu students''.

Her address came amidst protests in the US against the killing of African-American George Floyd by a white police officer in Minneapolis.

The country has been swept by protests since George Floyd's custodial death on May 25 with thousands of people mounting pressure for changes to the law enforcement practices.

The first-ever virtual Hindu commencement was organised by the Hindu Students Council on June 7, which drew thousands of viewers on Facebook and YouTube Live, all coming together in solidarity during the ongoing COVID-19 crisis.

According to Johns Hopkins Coronavirus Resource Center, the contagion has infected over 76,00,000 people and killed more than 4,25,000 across the world. The US is the worst affected country with over 2.04 million cases and more than 1,14,000 deaths.

The COVID-19, which originated in China''s Wuhan city in December last year, has also battered the world economy with the International Monetary Fund saying that the global economy is bound to suffer a "severe recession".

Scientists are racing against time to find a vaccine or medicine for its treatment.

Hundreds of graduates from the US, Canada, the UK, India and Australia attended to commemorate their graduation in a unique way - by celebrating their shared Hindu values.

Professor Subhash Kak served as the ceremony's Grand Marshall.

"As you think about this new chapter in your lives, ask yourself what is my purpose in life? It is a deep question that if you can recognise now that your purpose is to serve God and God''s children, practicing Karma Yoga, then you can lead a truly successful life," Tulsi Gabbard said.

"Success is not defined by temporary material things, trinkets, glittery objects or accomplishments - but a deeply successful and happy life centered around service," she added.

The Iraq war veteran ended her presidential campaign in March and offered her full support to former vice president Joe Biden, 77, who is all set to challenge Republican incumbent Donald Trump, 73, in November elections.

The commencement address focused heavily on themes from the Bhagavad Gita, a timeless historical text that many Hindus consider their moral framework.

Professor Kak, Regent Professor at Oklahoma State University and 2019 Padma Shri recipient, read out the names of the graduating students.

"I exhort you - the graduating students - to be the leaders of the new world where education is less of the mind of a vessel to be filled with information (usually forgotten after the semester is over), and more of a flame that is lit as envisioned by our Vedic sages," he said.

The student speakers were from many university campuses, including the Massachusetts Institute of Technology, Princeton, and Stanford.

Listen to the latest songs, only on JioSaavn.com

The programme included offerings of Hindu prayers, recitation of a traditional graduation message from the Upanishads, and a symbolic conferral of degrees to high school and college graduate.

Founded in 1990, Hindu Students Council is North America''s largest pan-Hindu youth organisation. 

Washington, May 19: As the scientists across the world are struggling to develop a vaccine for combating coronavirus, US drugmaker Moderna announced on Monday (local time) that the phase I trial of its Covid-19 vaccine has shown positive early results.

The company is hopeful that it's vaccine could be available to the public as early as January next year. Several firms across the world are in the race to develop a vaccine for the deadly virus which has claimed over 3 lakh lives worldwide.

CNN citing Dr. Tal Zaks, Moderna's chief medical officer reported that "if future studies go well, the company's vaccine could be available to the public as early as January".

"This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks was quoted as saying.

Moderna, based in Cambridge, Massachusetts announced that the vaccine developed neutralising antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from Covid-19, reported CNN.

These will be followed by phase 2 trials and phase 3 trials, which Moderna plans to start in July.

President Donald Trump had on Friday said that that the United States will be able to deliver a few hundred million doses of COVID-19 vaccine, under 'Operation Warp Speed', by the end of this year.

"I have very recently seen early data from a clinical trial with a coronavirus vaccine and this data made me feel even more confident that we'll be able to deliver a few hundred million doses of vaccine by the end of 2020 and we will do the best we can," Trump had said at a press conference at the White House on Friday.